Journal of the American College of Clinical Pharmacy : JACCP最新文献

Progress is being made in pharmacy's involvement in interprofessional continuing education 药剂学在跨专业继续教育中的参与正在取得进展

IF 1.3

Journal of the American College of Clinical Pharmacy : JACCP Pub Date : 2025-05-12 DOI: 10.1002/jac5.70032

Marilyn K. Speedie Ph.D.

引用次数: 0

Pharmacy practice expansion: The continued need for high-quality economic evaluations 药学实践扩展：对高质量经济评价的持续需求

IF 1.3

Journal of the American College of Clinical Pharmacy : JACCP Pub Date : 2025-05-12 DOI: 10.1002/jac5.70042

Glen T. Schumock Pharm.D., M.B.A., Ph.D., FCCP

引用次数: 0

Comment on “Pharmacist-managed diabetes care and change in A1C: A retrospective matched cohort study” “药剂师管理的糖尿病护理和A1C的变化：一项回顾性匹配队列研究”

IF 1.3

Journal of the American College of Clinical Pharmacy : JACCP Pub Date : 2025-04-13 DOI: 10.1002/jac5.70019

Bryan S. Sherwood Pharm.D., Jiazuo H. Feng M.D., Marilyn G. Hill Pharm.D., MHA

引用次数: 0

Artificial intelligence is here, but are we ready? 人工智能来了，但我们准备好了吗？

IF 1.3

Journal of the American College of Clinical Pharmacy : JACCP Pub Date : 2025-04-13 DOI: 10.1002/jac5.70021

Khoa A. Nguyen Pharm.D., Alan J. Zillich Pharm.D., FCCP

引用次数: 0

Additional comment on “Pharmacist-managed diabetes care and change in A1C: A retrospective matched cohort study” 对“药剂师管理的糖尿病护理和A1C变化：一项回顾性匹配队列研究”的补充评论

IF 1.3

Journal of the American College of Clinical Pharmacy : JACCP Pub Date : 2025-04-13 DOI: 10.1002/jac5.70029

Alexis Coffee Pharm.D., Daphne Smith Marsh Pharm.D., Abigail Elmes-Patel Pharm.D., MHPE

引用次数: 0

Gender-affirming care: A path toward inclusive healthcare 性别肯定护理：通往包容性医疗保健的道路

IF 1.3

Journal of the American College of Clinical Pharmacy : JACCP Pub Date : 2025-04-13 DOI: 10.1002/jac5.70020

Tam Phan Pharm.D., Kevin Astle Pharm.D., Alex Mills Pharm.D., Dustin Z. Nowaskie M.D.

引用次数: 0

Case series: Pain management and palliative care 病例系列：疼痛管理和姑息治疗

IF 1.3

Journal of the American College of Clinical Pharmacy : JACCP Pub Date : 2025-04-13 DOI: 10.1002/jac5.70023

John Bossaer Pharm.D.

引用次数: 0

A systematic review of economic evaluations of clinical pharmacy Services in the United States: 2018–2022 美国临床药学服务经济评价系统综述：2018-2022

IF 1.3

Journal of the American College of Clinical Pharmacy : JACCP Pub Date : 2025-04-11 DOI: 10.1002/jac5.70034

Bertha De Los Santos Pharm.D., M.S., Michael Kim Pharm.D., Abdullah Alsharif Pharm.D., Ahmed Gharib, Jessica Kim, Benson Binu B.S., Daniel Touchette Pharm.D., M.A., FCCP, Alexandra Perez Pharm.D., M.S.

{"title":"A systematic review of economic evaluations of clinical pharmacy Services in the United States: 2018–2022","authors":"Bertha De Los Santos Pharm.D., M.S., Michael Kim Pharm.D., Abdullah Alsharif Pharm.D., Ahmed Gharib, Jessica Kim, Benson Binu B.S., Daniel Touchette Pharm.D., M.A., FCCP, Alexandra Perez Pharm.D., M.S.","doi":"10.1002/jac5.70034","DOIUrl":"https://doi.org/10.1002/jac5.70034","url":null,"abstract":"Evaluating the economic impact of clinical pharmacy services (CPS) is important for program implementation and sustainability. This study systematically reviewed economic evaluations of United States-based CPS published between 2018 and 2022. A systematic search was conducted across PubMed, EMBASE, IPA, and CINAHL in September 2023. Inclusion criteria encompassed pharmacist-based CPS reporting economic outcomes or program costs. Studies where the pharmacist's individual economic impact could not be isolated were excluded. Study quality and risk of bias were assessed based on study design and the Quality of Health Economic Studies (QHES) instrument for full economic evaluations. Descriptive statistics summarized study characteristics. (PROSPERO #CRD42023449047). A total of 103 articles met inclusion criteria. Of these, 35% were disease state management, 28% general pharmacotherapy monitoring, and 27% targeted drug programs. Intervention settings included 35% hospital sites, 28% ambulatory care, and 9% community pharmacies. Telehealth delivery was reported in 36% of the studies, while 16% focused on outcomes related to reimbursement or return on investment. Economic evaluation types included descriptive (53%), partial evaluations (30%), and full economic evaluations (17%). According to the American College of Clinical Pharmacy process of care components, 57% included patient assessment, medication therapy evaluation, care plan development and implementation, and follow-up evaluation. The median and interquartile range (IQR) QHES score for the full evaluations was 68 (46–82) out of 100. This review highlights the need for improved methodological rigor and comprehensive economic evaluations to support the long-term viability and reimbursement of CPS, particularly among services delivered via telehealth.","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 5","pages":"385-397"},"PeriodicalIF":1.3,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143938742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Implementing use of cystatin C-guided estimated glomerular filtration rate for medication dosing at an Academic Medical Center 在一个学术医疗中心实施胱抑素c引导估计肾小球滤过率的用药剂量

IF 1.3

Journal of the American College of Clinical Pharmacy : JACCP Pub Date : 2025-04-10 DOI: 10.1002/jac5.70035

Victoria Williams Pharm.D., Rupal Parbhoo Pharm.D., Bruce Doepker Pharm.D., Claire Murphy Pharm.D., Lynn Wardlow Pharm.D., Kevin Kissling Pharm.D., Megan Bond Pharm.D., Kelly Bartsch Pharm.D., Sree Satyapriya M.D., Markisha Wilder M.S., Jessica Greco M.D., Anthony Gerlach Pharm.D.

{"title":"Implementing use of cystatin C-guided estimated glomerular filtration rate for medication dosing at an Academic Medical Center","authors":"Victoria Williams Pharm.D., Rupal Parbhoo Pharm.D., Bruce Doepker Pharm.D., Claire Murphy Pharm.D., Lynn Wardlow Pharm.D., Kevin Kissling Pharm.D., Megan Bond Pharm.D., Kelly Bartsch Pharm.D., Sree Satyapriya M.D., Markisha Wilder M.S., Jessica Greco M.D., Anthony Gerlach Pharm.D.","doi":"10.1002/jac5.70035","DOIUrl":"https://doi.org/10.1002/jac5.70035","url":null,"abstract":"Accurate kidney function assessment is essential for medication dosing, although traditional methods such as urine output and serum creatinine are limited, especially in patients with acute kidney injury. Cystatin C was made available as an alternative marker at our institution, prompting the formation of a multidisciplinary task force to guide its use and resolve discrepancies in clinical practice using a Plan-Do-Study-Act framework. Plan-Do-Study-Act is a validated approach to developing and evaluating interventions to ensure that changes to a process result in the desired improvement. The task force developed pharmacist-focused education, creating guidance documents and asynchronous training with competency assessments. An audit revealed that cystatin C was primarily used in intensive care units for dosing antibiotics like cefepime and vancomycin. In response, updates to clinical decision support systems in electronic medical records were made. A progress note template was designed and implemented to communicate cystatin C assessments and dosing changes based on this kidney filtration marker. Ongoing quality improvement efforts are focusing on broadening education, refining documentation, and researching optimal cystatin C use.","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 5","pages":"376-384"},"PeriodicalIF":1.3,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jac5.70035","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143939112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Creating a dashboard for oversight of a comprehensive medication management program for patients with type 2 diabetes in a large municipal health care system in the United States 在美国的一个大型市政卫生保健系统中，为2型糖尿病患者创建一个综合药物管理项目监督的仪表板

IF 1.3

Journal of the American College of Clinical Pharmacy : JACCP Pub Date : 2025-03-19 DOI: 10.1002/jac5.70026

Joshua P. Rickard Pharm.D., MPH, Susan Zhou M.S., Navin Kumar Ph.D., Hannah B. Jackson M.D., MPH, Kevin Chen M.D., MHS

{"title":"Creating a dashboard for oversight of a comprehensive medication management program for patients with type 2 diabetes in a large municipal health care system in the United States","authors":"Joshua P. Rickard Pharm.D., MPH, Susan Zhou M.S., Navin Kumar Ph.D., Hannah B. Jackson M.D., MPH, Kevin Chen M.D., MHS","doi":"10.1002/jac5.70026","DOIUrl":"https://doi.org/10.1002/jac5.70026","url":null,"abstract":"Type 2 Diabetes Mellitus (T2DM) is a prevalent and costly condition, particularly affecting racial/ethnic minorities and low-income populations in the United States. Comprehensive Medication Management (CMM) programs, where clinical pharmacists co-manage patients alongside primary care physicians, offer a team-based approach that has been shown to improve diabetes care. However, managing CMM programs across multiple sites presents operational challenges that can be addressed through digital tools. This “how-to” guide provides an overview of developing and implementing a CMM Dashboard to enhance program management and patient outcomes in a large municipal health care system. Key components include tracking patient demographics, clinical outcomes (e.g., hemoglobin A1c, blood pressure), and operational metrics across 21 sites. Practical applications of the dashboard are outlined with a focus on real-time data analysis, care gap identification, and optimizing resource utilization. By consolidating comprehensive program data, the CMM Dashboard supports clinical decision-making, informs leadership on program performance, and enables targeted interventions to improve health outcomes for underserved populations.","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 5","pages":"358-366"},"PeriodicalIF":1.3,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143938793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0